Upgrade to Pro — share decks privately, control downloads, hide ads and more …

RNA-quality-degradation

 RNA-quality-degradation

Applying Statistical Correction for Brain Tissue RNA Degradation to Gene Expression Differences in Schizophrenia

References:
BrainSeq: A Human Brain Genomics Consortium. Brainseq: neurogenomics to drive novel target discovery for neuropsychiatric disorders. Neuron 2015;88(6):1078-1083. doi:10.1016/j.neuron.2015.10.047.
Jaffe AE, Tao R, Norris AL, et al. qSVA framework for RNA quality correction in differential expression analysis. Proc Natl Acad Sci USA 2017;114(27):7130-7135. doi:10.1073/pnas.1617384114.
Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 2007;3(9):1724-1735. doi:10.1371/journal.pgen.0030161.

Amy Peterson

May 04, 2018

Transcript

21 slides
  1. 11 Applying Statistical Correction for Brain Tissue RNA Degradation to

    Gene Expression Differences in Schizophrenia Amy Peterson Capstone Advisors: Andrew Jaffe, PhD Leonardo Collado-Torres, PhD
  2. 2018 Elon Musk put a Tesla in space THE SCIENTIFIC

    FRONTIER 65+ YEARS: WAITING FOR A BREAKTHROUGH Molecular targets of all current psychotherapeutic drugs are the same as their 1950’s prototypes. 1957 Sputnik I 1952 Discovery of Antipsychotic Chlorpromazine (DRD2 blockade) 2018 Antipsychotics for treatment of schizophrenia all work via DRD2 blockade ? 2
  3. Animal Models Neuronal Cell Models Drug Discovery New Treatments 2300+

    Human postmortem brains 1000+ Cell lines from individuals Genomics + Transcriptomics + Proteomics 3 Mechanisms of Illness Clinical Genetics BrainSeq: A Human Brain Genomics Consortium THE SCIENTIFIC FRONTIER
  4. Animal Models Neuronal Cell Models Drug Discovery New Treatments 2300+

    Human postmortem brains 1000+ Cell lines from individuals Genomics + Transcriptomics + Proteomics 4 Mechanisms of Illness Clinical Genetics BrainSeq: A Human Brain Genomics Consortium DLPFC 495 samples BrainSeq Phase I polyA Jaffe et al., bioRxiv, 2017 THE SCIENTIFIC FRONTIER
  5. Animal Models Neuronal Cell Models Drug Discovery New Treatments 2300+

    Human postmortem brains 1000+ Cell lines from individuals Genomics + Transcriptomics + Proteomics 5 Mechanisms of Illness Clinical Genetics BrainSeq: A Human Brain Genomics Consortium DLPFC 495 samples BrainSeq Phase I polyA Jaffe et al., bioRxiv, 2017 DLPFC 453 samples HIPPO 447 samples BrainSeq Phase II RiboZero THE SCIENTIFIC FRONTIER
  6. BACKGROUND 6 RESEARCH QUESTION Do patients with schizophrenia exhibit gene

    expression differences across various brain regions compared to non-psychiatric controls?
  7. BACKGROUND 7 RESEARCH QUESTION Do patients with schizophrenia exhibit gene

    expression differences across various brain regions compared to non-psychiatric controls? • Impact of RNA quality? • Functionality of genes identified as differentially expressed?
  8. SAMPLE SIZE 9 • 712 total RNA-seq samples • 379

    DLPFC, 333 HIPPO • 447 Individuals • 177 Schizophrenia cases • 270 Non-psychiatric controls Dataset summary DLPFC HIPPO CASE 153 133 CONTROL 226 200 DLPFC 453 samples HIPPO 447 samples
  9. DEqual HIPPO 15 Model 1 (6429 genes) Model 1. Naïve

    model E = 0 + 1 DEqual plots demonstrate effectiveness of statistical correction HIPPO 333 samples r = 0.412
  10. DEqual HIPPO 16 Model 1 (6429 genes) Model 2 (63

    genes) Model 1. Naïve model E = 0 + 1 Model 2. Added RNA-quality and demographic covariates E = 0 + 1 + 2 + 3 + 4 + 5 te + 6 + 7 + ∑ γ ^ _`a DEqual plots demonstrate effectiveness of statistical correction HIPPO 333 samples r = 0.412 r = 0.0712
  11. DEqual HIPPO 17 Model 1 (6429 genes) Model 2 (63

    genes) Model 3 (48 genes) Model 1. Naïve model E = 0 + 1 Model 2. Added RNA-quality and demographic covariates E = 0 + 1 + 2 + 3 + 4 + 5 te + 6 + 7 + ∑ γ ^ _`a Model 3. Added qSVs E = 0 + 1 + 2 + 3 + 4 + 5 te + 6 + 7 + ∑ γ ^ _`a + ∑ Ζ h _`a DEqual plots demonstrate effectiveness of statistical correction HIPPO 333 samples r = 0.412 r = 0.0712 r = -0.00173
  12. DIFFERENTIAL EXPR 18 A B Comparing differentially expressed genes •

    A. T-statistics for top 400 differentially expressed genes for HIPPO compared to DLPFC (blue line: regression, red line: loess) • B. BrainSeq Phase 2 and BrainSeq Phase 1 (BSP1) DLPFC −6 −4 −2 0 2 4 −4 −2 0 2 4 t−statistic HIPPO t−statistic DLPFC r = 0.644 −6 −4 −2 0 2 4 6 −6 −4 −2 0 2 4 6 t−statistic DLPFC t−statistic BSP1 r = 0.809
  13. SUMMARY 19 • Statistical correction successfully removed confounding effect of

    RNA quality (DEqual plots) • Findings comparable with previous use of qSVA in BrainSeq Phase I (DLPFC) Final Model E = 0 + 1 + 2 + 3 + 4 + 5 te + 6 + 7 + ∑ ^ _`a + ∑ Ζ h _`a
  14. REFERENCES 20 References BrainSeq: A Human Brain Genomics Consortium. Brainseq:

    neurogenomics to drive novel target discovery for neuropsychiatric disorders. Neuron 2015;88(6):1078-1083. doi:10.1016/j.neuron.2015.10.047. Jaffe AE, Tao R, Norris AL, et al. qSVA framework for RNA quality correction in differential expression analysis. Proc Natl Acad Sci USA 2017;114(27):7130-7135. doi:10.1073/pnas.1617384114. Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 2007;3(9):1724-1735. doi:10.1371/journal.pgen.0030161. Code: https://github.com/LieberInstitute/qsva_brain JHPCE Cluster. https://jhpce.jhu.edu >838,168 linear regressions All analyses completed in R 3.4 Resources and Reproducibility
  15. THANK YOU! Questions? Amy Peterson MPH Candidate 2018 [email protected] amy-peterson.github.io

    21 Acknowledgements • Andrew Jaffe and lab members • BrainSeq Consortium • Leonardo Collado-Torres

More Decks by Amy Peterson

Other Decks in Science